Lauseker, Michael <br/><br/>
Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.  [electronic resource] 

 -  Haematologica  May 2012 
 - e14-5 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2011.061630  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Piperazines--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrimidines--administration & dosage